Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

170.00USD
17 Nov 2017
Change (% chg)

$-0.77 (-0.45%)
Prev Close
$170.77
Open
$170.67
Day's High
$171.09
Day's Low
$169.54
Volume
2,039,739
Avg. Vol
2,618,421
52-wk High
$191.10
52-wk Low
$138.83

Latest Key Developments (Source: Significant Developments)

Amgen launches Enbrel Mini with Autotouch in U.S.
Friday, 17 Nov 2017 09:00am EST 

Nov 17 (Reuters) - Amgen Inc :Amgen launches the Enbrel Mini single-dose prefilled cartridge with autotouch reusable autoinjector that is ergonomically designed for patients.Enbrel Mini with autotouch is now available in United States​.  Full Article

Temasek Holdings takes share stake in Vantiv Inc, raises share stake in Amgen
Tuesday, 14 Nov 2017 07:13am EST 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd :Temasek Holdings (Private) Ltd takes share stake of 982,057 Class A shares in Vantiv Inc <<>> - SEC filing.Temasek Holdings (Private) Ltd raises share stake in Emerson Electric Co to 28,000 shares from 5,146 shares.Temasek Holdings (Private) Ltd raises share stake in Amgen Inc by about 25 percent to 188,527 shares.Temasek Holdings (Private) Ltd raises share stake in Biogen Inc by about 25 percent to 118,644 shares.Temasek Holdings (Private) Ltd - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.Source text for quarter ended Sept 30, 2017 (http://bit.ly/2yBi2ic).Source text for quarter ended June 30, 2017: (http://bit.ly/2vUxgkf).  Full Article

Amgen receives positive CHMP opinion to expand use of Nplate in pediatric patients with chronic immune thrombocytopenic purpura
Friday, 10 Nov 2017 07:29am EST 

Nov 10 (Reuters) - Amgen Inc :Amgen receives positive CHMP opinion to expand use of Nplate® (romiplostim) in pediatric patients with chronic immune thrombocytopenic purpura.Amgen Inc - ‍positive CHMP opinion was based on five studies evaluating safety and efficacy of Nplate in children with ITP​, among other things.  Full Article

Amgen and Allergan receive positive chmp opinion for ABP 215
Friday, 10 Nov 2017 07:28am EST 

Nov 10 (Reuters) - Allergan Plc :Amgen and Allergan receive positive CHMP opinion for ABP 215 (biosimilar bevacizumab) for the treatment of certain types of cancer.Amgen Inc - ‍CHMP positive opinion will now be reviewed by European Commission, which has authority to approve medicines for European Union​.  Full Article

Amgen, Novartis announce expanded collaboration with Banner Alzheimer's Institute
Thursday, 2 Nov 2017 04:30pm EDT 

Nov 2 (Reuters) - Amgen Inc :Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program.Amgen - Co, ‍Novartis announced expanded collaboration with Banner Alzheimer's Institute to initiate new trial - API Generation Study 2​.  Full Article

‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​
Tuesday, 31 Oct 2017 02:44am EDT 

Oct 31 (Reuters) - Amgen Inc :‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​.‍Under terms of agreement, ‍Kirin-Amgen joint venture will pay $780 million to Kirin​.‍Kirin-Amgen will become a wholly-owned subsidiary of Amgen​.‍Joint venture ‍Kirin-Amgen will redeem Kirin's shares ​.‍Will make additional payments to Kirin upon occurrence of certain sales​.‍As sole shareholder of ‍Kirin-Amgen, Amgen will own product rights and remaining cash held by ‍Kirin-Amgen .‍License agreements between ‍Kirin-Amgen and KHK in certain Asian territories will remain in place​.  Full Article

‍Kymera Therapeutics announces $30 mln series A financing round​
Monday, 30 Oct 2017 07:00am EDT 

Oct 30 (Reuters) - :‍Kymera Therapeutics Llc announces $30 million series a financing round​.‍Kymera Therapeutics Llc - financing round was led by Atlas Venture, along with Lilly Ventures and Amgen Ventures​.  Full Article

Amgen reports Q3 non-GAAP earnings per share of $3.27
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Amgen Inc : :Amgen - Qtrly total revenue fell 1 percent to $5.77 billion.Qtrly GAAP earnings per share $2.76.Qtrly non-GAAP earnings per share $3.27.Amgen says incurred $67 million of pre-tax expenses, or $0.07 eps, in Q3 related to Hurricane Maria.Amgen says in Q4, expects additional pre-tax expenses in the range of $75 million to $100 million, or $0.08 to $0.11 EPS related to Hurricane Maria.Amgen says does not expect a significant impact to full-year 2018 results from Hurricane Maria.Amgen - Qtrly GAAP earnings per share, operating income impacted by non-cash charges associated with decision to discontinue internal development of AMG 899.Amgen says 2017 GAAP EPS guidance revised to $10.96 to $11.20 and non-GAAP EPS guidance increased to $12.50 to $12.70.Amgen says 2017 total revenue guidance revised to $22.7 billion to $23.0 billion.Amgen Inc Q3 earnings per share view $3.11, revenue view $5.76 billion -- Thomson Reuters I/B/E/S.Amgen Inc FY2017 earnings per share view $12.58, revenue view $22.86 billion -- Thomson Reuters I/B/E/S.Amgen Inc says in Oct. 2017, board approved increase in remaining share repurchase authorization for aggregate authorization of $5 billion.  Full Article

Amgen ‍board declares $1.15 per share dividend for Q4
Tuesday, 24 Oct 2017 04:00pm EDT 

Oct 24 (Reuters) - Amgen Inc :Amgen Inc - ‍board of directors declared a $1.15 per share dividend for Q4 of 2017​.  Full Article

Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint
Monday, 23 Oct 2017 04:00pm EDT 

Oct 23 (Reuters) - Amgen Inc :Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS(carfilzomib) regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients.Amgen Inc - ‍overall safety profile of once-weekly KYPROLIS regimen was comparable to that of twice-weekly regimen​.  Full Article

BRIEF-Amgen launches Enbrel Mini with Autotouch in U.S.

* Amgen launches the Enbrel Mini single-dose prefilled cartridge with autotouch reusable autoinjector that is ergonomically designed for patients